Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Day One Biopharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2025 was 157.94.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Day One Biopharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Day One Biopharmaceuticals's Cash-to-Debt or its related term are showing as below:
DAWN'
s Cash-to-Debt Range Over the Past 10 Years
Min: 108.78 Med: 421 Max: No Debt
Current: 157.94
During the past 7 years, Day One Biopharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 108.78. And the median was 421.00.
DAWN's Cash-to-Debt is not ranked
in the Biotechnology industry.
Industry Median: 6.72
vs DAWN: 157.94
Day One Biopharmaceuticals (NAS:DAWN) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Day One Biopharmaceuticals Cash-to-Debt Related Terms
Day One Biopharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Day One Biopharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Day One Biopharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Day One Biopharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Day One Biopharmaceuticals (DAWN) has a Cash-to-Debt of 157.94 as of Dec. 2025. This is 62% below median its historical median of 421.00. Over the past decade, Day One Biopharmaceuticals' Cash-to-Debt has ranged from 108.78 to 10,000.00.
Is Day One Biopharmaceuticals' Cash-to-Debt too high?
Day One Biopharmaceuticals' current Cash-to-Debt of 157.94 is 62% below median its 10-year median of 421.00. Over the past 10 years, this metric has ranged from a low of 108.78 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.72. Day One Biopharmaceuticals' value of 157.94 is 2250.3% above this industry median. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Cash-to-Debt compare to TYRA and DFTX?
Day One Biopharmaceuticals' Cash-to-Debt of 157.94 can be compared against companies in the Biotechnology industry. The industry median Cash-to-Debt is 6.72. Day One Biopharmaceuticals' value of 157.94 is 2250.3% above this benchmark. Historically, Day One Biopharmaceuticals' own Cash-to-Debt has ranged from 108.78 to 10,000.00 over the past decade. While the company's 10-year median is 421.00 vs. the industry median of 6.72, Day One Biopharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Day One Biopharmaceuticals's current Cash-to-Debt of 157.94 is 2250.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Day One Biopharmaceuticals's current Cash-to-Debt is 157.94, which is 62% below median its own 10-year median of 421.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Cash-to-Debt of 157.94. The current Cash-to-Debt is 157.94, which is 62% below median its 10-year median of 421.00 and 2250.3% above the Biotechnology industry median of 6.72. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Cash-to-Debt is 157.94 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score
Get the complete analysis for DAWN
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DAWN has been successfully added to your 
